7 results about "Galactitol" patented technology

The invention belongs to the technical field of preparation of galactitol, and particularly relates to a method for preparing galactitol by taking lactose as a raw material. Comprising the following steps: S1, preparation of an adsorption column: preparing phenylboronic acid polymer microspheres and packing the microspheres into a column to obtain the adsorption column; s2, enzymolysis: carrying out enzymolysis on the lactose solution through lactase to obtain enzymatic hydrolysate; s3, monosaccharide separation: filtering the enzymatic hydrolysate, adjusting the pH value to be alkaline, passing through an adsorption column to obtain a glucose-rich solution, and enabling an eluent to flow through the adsorption column to obtain a galactose-rich solution; and S4, hydrogenation: carrying out ion exchange, concentration, hydrogenation, decoloration, ion exchange, concentration and crystallization on the galactose pregnant solution to obtain galactitol. According to the invention, galactose with a cis-vicinal diol structure can be adsorbed by the phenylboronic acid polymer carrier, so that glucose and galactose which are difficult to separate by chromatographic separation are separated, and a production process for preparing galactitol by taking lactose as a raw material is realized.

The invention belongs to the technical field of plant disease prevention and control, and particularly relates to application of a plant source compound preparation to prevention and control of tea tree anthracnose. The plant source compound preparation is prepared from plant secondary metabolites and a plant resistance inducer; the mass ratio of the plant secondary metabolite to the plant resistance inducer is 1: (0.1-10000); the plant secondary metabolite is selected from at least one of galactitol, 1-methyl nicotinate, caffeine, anthocyanin and quercetin; the plant resistance inducer comprises any one of methyl jasmonate, jasmonic acid and salicylic acid. The plant source compound preparation provided by the invention can realize disease prevention and control through double ways of direct bacteriostasis and host immunity activation, the prevention and control effect can be remarkably improved, and the use amount of each component is reduced, so that the production cost and the pollution to the environment are reduced.

A surfactant of Formula (I), wherein: R1=residue derived from a rosin acid; X=H, C1-C20-alkyl, P=O(OR2)(OR3) or SO3R4; Y=H, P=O(OR2)(OR3), SO3R4; A=(EO)r-(PO)s, or a residue derived from a diol or a polyol selected among polyglycerol, propane-1,3-diol, glycerol, trimethylolethane, trimethylolpropane, sorbitan, sorbitol, isosorbide, erythritol, threitol, pentaerythritol, arabitol, xylitol, ribitol, fucitol, mannitol, galactitol, iditol, inositol, volemitol or glucose; R2, R3 and R4=hydrogen, an alkali metal, ammonium ion, a protonated amine, a quaternary organic ammonium or an alkaline earth metal; EO=CH2CH2O; PO=CH2CH(CH3)O; n is an integer number ranging from 1 to 10; p and q are integer numbers ranging from 0 to 100; r and s are integer numbers ranging from 0 to 100, with the proviso that the sum r+s is at least 1.

The application discloses a kind of phosphated cellulose synergistically enhanced flame-retardant composite phase change materials and preparation method thereof, belong to thermal management material technical field.Preparation method includes steps: the eutectic phase change material CPCM of specific mass ratio of mannitol and galactitol is invented;Preparation MC@rGO skeleton, and with CPCM composite preparation CPCM / MC@rGO;Cellulose is modified in situ phosphated to obtain P-CSF, and rGO is polymerized to form P-CSF@rGO skeleton, then with above-mentioned CPCM composite obtains CPCM / P-CSF@rGO.The material prepared in the application retains up to 152.7 J / g latent heat of phase change and 1.039 W / (m•K) high thermal conductivity, while the limiting oxygen index LOI is improved to 30.64%, the material is endowed with high flame retardant properties, and it also has flexibility, realizes the synergistic enhancement of heat storage, heat conduction and flame retardant performance, and the material is especially suitable for advanced energy systems and electronic devices with strict requirements on thermal safety, energy storage density and thermal management efficiency.

The invention relates to the technical field of medical auxiliary materials, and provides a starch-based capsule material and a preparation method thereof.The starch-based capsule material is prepared from, by weight, 60-80 parts of modified starch, 1.5-3.5 parts of gel, 3-6 parts of plasticizer and 150-200 parts of water; the plasticizer comprises glycerol, epoxidized soybean oil and galactitol in a mass ratio of 1: 2: (0.2-1.2). Through the technical scheme, the problem of poor toughness of the starch-based capsule in the prior art is solved.

The application discloses a D-tagatose-producing strain and application thereof, the strain is classified and named as endogenous bacillus (Bacillus endophyticus) (Bacillus endophyticus) Z723, and has a preservation number of GDMCC No: 63266. Priestia endophytica The strain utilizes galactitol as a substrate to produce D-tagatose through a whole-cell catalysis method, and the conversion rate can reach 92%. The strain provides a new strain for high-conversion-rate D-tagatose synthesis and related oxidoreductase mining, and has a wide application prospect in the fields of food and medical treatment.

The invention relates to the technical field of medical kits, and provides a potential serum marker for diagnosing inhalation pneumonia, the biomarker is selected from six kinds of materials including quinolinic acid, phosphatidylcholine (18: 0 / 20: 4 (5Z, 8Z, 11Z, 14Z)), N6, N6, N6-trimethyl-L-lysine, lysophosphatidylcholine (17: 0 / 0: 0), DL-piperidine acid and galactitol. The kit comprises a calibration product, a low-value quality control product, a high-value quality control product, an internal standard product, a protein precipitant, a diluent, an electrolyte concentrated solution I and an electrolyte concentrated solution II, the six biomarkers can accurately identify the inhaled pneumonia and the non-inhaled pneumonia, and the kit is developed around the six biomarkers. The method can well identify inhalation pneumonia and non-inhalation pneumonia, and solves the technical problem of missed diagnosis of patients with early-stage inhalation pneumonia.